Overall CBC | ER+/PR+ CBC | ER+/PR- CBC | ER-/PR- CBC | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
N (cases/controls) | RRa (95% CI) | RRb (95% CI) | N (cases/controls) | RRa (95% CI) | RRb (95% CI) | N (cases/controls) | RRa (95% CI) | RRb (95% CI) | N (cases/controls) | RRa (95% CI) | RRb (95% CI) | |
All women tested for BRCA1/2 mutationsc, tumor status at first diagnosis | ||||||||||||
ER status | ||||||||||||
Positive | 336/745 | 1.0 (ref.) | 1.0 (ref.) | 100/179 | 1.0 (ref.) | 1.0 (ref.) | 41/66 | 1.0 (ref.) | 1.0 (ref.) | 26/114 | 1.0 (ref.) | 1.0 (ref.) |
Negative | 193/338 | 1.4 (1.1, 1.9) | 1.2 (0.9, 1.6) | 22/82 | 0.6 (0.3, 1.2) | 0.7 (0.3, 1.3) | 15/31 | 0.8 (0.3, 2.0) | 0.8 (0.3, 2.0) | 56/56 | 4.6 (2.1, 10.2) | 3.8 (1.6, 8.9) |
Other/unknownd | 176/315 | 33/44 | 9/30 | 19/32 | ||||||||
PR status | ||||||||||||
Positive | 287/615 | 1.0 (ref.) | 1.0 (ref.) | 88/160 | 1.0 (ref.) | 1.0 (ref.) | 35/61 | 1.0 (ref.) | 1.0 (ref.) | 23/95 | 1.0 (ref.) | 1.0 (ref.) |
Negative | 172/318 | 1.3 (1.0, 1.7) | 1.1 (0.8, 1.5) | 26/86 | 0.8 (0.4, 1.5) | 0.8 (0.5, 1.5) | 16/20 | 2.2 (0.7, 6.8) | 2.2 (0.7, 6.8) | 56/55 | 5.3 (2.3, 12.2) | 6.8 (2.6, 17.6) |
Other/unknownd | 246/465 | 41/59 | 14/46 | 22/52 | ||||||||
Joint ER/PR status | ||||||||||||
ER+/PR+ | 250/536 | 1.0 (ref.) | 1.0 (ref.) | 84/143 | 1.0 (ref.) | 1.0 (ref.) | 29/46 | 1.0 (ref.) | 1.0 (ref.) | 16/86 | 1.0 (ref.) | 1.0 (ref.) |
ER+/PR- | 38/85 | 1.1 (0.7, 1.7) | 1.1 (0.7, 1.7) | 9/22 | 0.9 (0.3, 2.3) | 0.8 (0.3, 2.2) | 7/4 | 4.9 (0.9, 26.5) | 5.0 (0.9, 27.3) | 8/14 | 4.6 (1.3, 16.4) | 5.3 (1.3, 21.5) |
ER-/PR- | 132/221 | 1.5 (1.1, 2.1) | 1.2 (0.9, 1.7) | 17/61 | 0.7 (0.3, 1.5) | 0.8 (0.4, 1.6) | 9/16 | 1.2 (0.3, 4.7) | 1.2 (0.3, 4.6) | 48/41 | 7.6 (3.0, 19.5) | 8.9 (3.1, 25.9) |
Other/unknownd.e | 285/556 | 45/79 | 20/61 | 29/61 | ||||||||
BRCA1/2 non-carriers only, tumor status at first diagnosis | ||||||||||||
ER status | ||||||||||||
Positive | 307/716 | 1.0 (ref.) | 89/178 | 1.0 (ref.) | 39/64 | 1.0 (ref.) | 23/106 | 1.0 (ref.) | ||||
Negative | 137/304 | 1.2(0.9, 1.7) | 19/70 | 0.7 (0.3, 1.5) | 12/29 | 0.4 (0.1, 1.4) | 33/52 | 3.6 (1.4, 8.9) | ||||
Other/unknownd | 152/302 | 30/42 | 9/29 | 14/32 | ||||||||
PR status | ||||||||||||
Positive | 261/593 | 1.0 (ref.) | 81/159 | 1.0 (ref.) | 32/59 | 1.0 (ref.) | 18/88 | 1.0 (ref.) | ||||
Negative | 122/286 | 1.0 (0.8, 1.4) | 21/75 | 0.8 (0.4, 1.7) | 14/19 | 1.6 (0.5, 5.3) | 36/52 | 6.7 (2.4, 18.9) | ||||
Other/unknownd | 213/443 | 36/56 | 14/44 | 16/50 | ||||||||
Joint ER/PR status | ||||||||||||
ER+/PR+ | 233/520 | 1.0 (ref.) | 77/143 | 1.0 (ref.) | 27/45 | 1.0 (ref.) | 15/80 | 1.0 (ref.) | ||||
ER+/PR- | 31/78 | 0.9 (0.5, 1.4) | 7/22 | 0.7 (0.2, 2.0) | 7/4 | 4.4 (0.8, 23.6) | 6/13 | 3.8 (0.8, 17.2) | ||||
ER-/PR- | 90/197 | 1.2 (0.8, 1.8) | 14/50 | 0.9 (0.4, 2.0) | 7/15 | 0.6 (0.1, 2.8) | 30/39 | 7.7 (2.6, 23.3) | ||||
Other/unknownd,e | 242/527 | 40/75 | 19/58 | 19/58 |